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Objective: To compare the methods of transcervical resectoscopy versus dilation and curettage (D&C) for
endometrial biopsy and to compare these methods for the percentage of histological upgrades at the
ﬁnal posthysterectomy pathology ﬁndings in endometrial cancer.
Materials and methods: We retrospectively reviewed 253 cases of uterine cancer diagnosed from May
1995 to January 2014. Included in the study were patients who received transcervical resectoscopy (TCR)
or D&C biopsy as the diagnostic method and underwent laparoscopic staging at our institution. The
International Federation of Gynecologists and Obstetricians (FIGO) grade in the pathological report of the
biopsy and ﬁnal hysterectomy were recorded. The extrauterine risk was stratiﬁed using the initial FIGO
grade and depth of myometrium invasion. It was compared to the actual risk using ﬁnal pathological
ﬁndings.
Results: We identiﬁed 203 cases of endometrial cancer; 18 (8.9%) patients had a higher histological grade
at the ﬁnal hysterectomy. Among the 203 patients, 76 patients underwent TCR biopsy and 127 under-
went D&C biopsy. The histological grade was upgraded in two (2.6%) patients in the TCR group. Three
(3.9%) patients had positive peritoneal washings. In the D&C group, 16 (12.6%) patients with three (2.4%)
positive peritoneal washings were upgraded.
Conclusion: Transcervical resectoscopy could provide more precise grading information, compared to
D&C (2.6% vs. 12.6%). Doctors could therefore make a more accurate staging plan, based on the preop-
erative risk evaluation.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Endometrial cancer is the most common gynecological malig-
nancy in Western countries. In the United States alone, the inci-
dence of endometrial cancers increased from approximately 40,320
new cases in 2004 to an estimated 49,560 new cases in 2013 [1,2].
In the past, multiple attempts to evaluate the histological grade
preoperatively were without signiﬁcant success [4,7]. Dilation and
curettage (D&C) was once the gold standard for endometrialnd Gynecology, Chang Gung
i-Shan, Taoyuan City 33305,
bstetrics & Gynecology. Publishedsampling and routinely used with an upgrade rate of 17e26%,
compared to the ﬁnal pathology [8e10]. In an attempt to develop a
less invasive diagnostic method, ofﬁce endometrial sampling
became progressively popular. However, studies aimed at investi-
gating ofﬁce biopsies revealed an apparent inaccuracy in histo-
logical grading with an upgrade rate of nearly 30%, compared to
hysterectomy pathology [11]. Cutillo et al [12] investigated the ac-
curacy of transcervical resectoscopy (TCR) and revealed a rather
optimistic ﬁnding of 97.1% correlationwith the ﬁnal pathology. This
could be a solution to overcome the hurdle of inevitable upgrades.
This method allows direct visualization, a targeted biopsy, and
theoretically a more accurate evaluation of preoperative tumor
grading. The purpose of this study was to compare the accuracy of
TCR biopsy versus D&C biopsy performed before hysterectomy in
patients with endometrial cancer to establish a more accurateby Elsevier Taiwan LLC. All rights reserved.
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treat patients with endometrial cancer.
Materials and methods
After we gained approval from our Chang Gung Medical Foun-
dation Institutional Review Board, we retrospectively reviewed 253
cases of uterine cancer that were treated at our institution from
May 1995 to January 2014. We reviewed the patients' information
from the time of diagnosis until the date of the most recent follow
up. All patients underwent TCR or D&C biopsy at our institution or
underwent a D&C biopsy as the diagnostic procedure at a local
medical department, and received laparoscopic hysterectomy or
staging as the treatment by our minimally invasive surgical team.
All patients who received a diagnosis outside of our institution
were asked to provide the original slides, which were reviewed by
our own pathologist.
Patients were also excluded if they had a biopsy during the of-
ﬁce hysteroscopy. We excluded women whose endometrial cancer
was an incidental ﬁnding during hysterectomies performed for
other indications. Women with uterine sarcomas detected during
the preoperative biopsy were excluded. Patients were included if
their preoperative histological grade, based on D&C or TCR exam-
ination, was described in the pathology report.
We abstracted data from electronic medical records. When
electronic medical records were unavailable, we abstracted data
from the patients' original records. Patients whose charts and in-
formation were incomplete or missing were excluded. Pathological
and surgical records were reviewed for histiotype, ﬁnal patholog-
ical grade, number of resected lymph nodes, lymphovascular space
invasion, cervical invasion, adnexa invasion, and washing cytology.
After analyzing preoperative patient risk, we categorized the
patients into the TCR group or the D&C group. For each group, we
compared the biopsy histological grade with the ﬁnal hysterectomy
grade of patients who were upgraded in the ﬁnal pathology. We
analyzed the end results. All data were calculated and descriptive
statistics were performed using SPSS for Windows (version 17.0.0;
IBM SPSS, Inc., Chicago, IL, USA).
Results
Using the aforementioned criteria, we included 203 patients.
Seventy-six patients underwent a TCR biopsy and 127 patients
underwent a D&C biopsy. The mean age of the TCR group patients
was 49.7 years, and 48.7% patients had a preoperative diagnosis of
Grade 1; 26.3% of patients, Grade 2; and 25.0% of patients, Grade 3.
The mean age of women in the D&C group was 54.1 years, and
62.2% of patients had a preoperative diagnosis of Grade 1; 21.3% of
patients, Grade 2; and 16.5% of patients, Grade 3. Table 1 summa-
rizes other ﬁndings of our patients. All parameters between the two
groups were statistically insigniﬁcant.
Among 76 patients who underwent TCR biopsy, only two pa-
tients were upgraded in the ﬁnal pathology, which gives an up-
grade rate of 2.6% (Table 2). Both patients had mixed type
endometrioid adenocarcinoma: the ﬁrst patient had mucinous
papillary carcinoma, and the second patient had serous papillary
carcinoma.
As Table 3 shows, in the D&C group of 127 patients, 16 (12.6%)
patients were upgraded. These included type I histiotype (i.e., low
grade) and type II histiotype (i.e., high grade, serous papillary, clear
cell). Of the upgraded cases, eight (6.3%) patients initially diagnosed
with Grade 1 were upgraded to Grade 2, and two (1.6%) patients
initially diagnosed with Grade 1 were upgraded to Grade 3 at the
ﬁnal pathology. The diagnosis of six (4.7%) patients was upgraded
from Grade 2 to Grade 3.Only three patients had positive peritoneal cytology washings at
the time of surgery. Of these three patients, two patients had
disseminated Stage III disease with a high histological grade (Stage
IIIA, Grade 3 and Stage IIIC1, Grade 3), and one patient had early
Stage IA, Grade 2, and <5% myometrium invasion (see Table 4).
Discussion
The primary endpoint of our study was to compare TCR versus
D&C for endometrial biopsy and to compare the percentage of
histological upgrades at the ﬁnal posthysterectomy pathology in
endometrial cancer. Preoperative tumor evaluation in endometrial
cancer is crucial in risk stratiﬁcation and intraoperative manage-
ment. Determination of the tumor grade combined with the depth
of myometrium invasion can alter a surgeon's decision in
completing surgical staging of patients at high risk for extrauterine
disease, whereas it may be unnecessary in low-risk patients. In the
past, multiple studies aimed to stratify the risk for extrauterine
disease to determine the management and treatment of patients
with endometrial cancer [3,14,15,17]. Preoperative evaluation of the
extrauterine risk facilitates a surgeon's decision to perform
comprehensive lymph node dissection. According to an earlier
study by the Gynecology Oncology Group [3] in 1987, assessing the
extrauterine risk is accomplished by evaluating the depth of myo-
metrium invasion and histological grade. A low risk is typically
described as any grade without myometrial invasion or as Grade 1
with minimal myometrial invasion. [3,5,13,16]. However, based on
these criteria, it is difﬁcult to accurately evaluate because of mul-
tiple limitations. Histological grades are often upgraded when
compared to the ﬁnal pathology after a hysterectomy. In endome-
trial sampling, upgrade rates up to 27% have been reported
[8,28e31]. Our study obtained an upgrade rate of 13% between the
D&C biopsy and the ﬁnal hysterectomy grade, which is compatible
with a previous series showing a 15% upgrade rate [8], and reports
showing an upgrade rate of up to 26% for Grades 1 and 2 [10]. A
previous prospective study showed that TCR has a 97.1% correlation
with the ﬁnal hysterectomy histopathological grade [12]. We ob-
tained similar results with 97.3% correlation and only a 2.6% up-
grade. This correlation is much higher than that for D&C.
In the past, studies have attempted to resolve the issue of up-
grades at the ﬁnal hysterectomy pathology. Investigators concluded
that D&C blindly scrapes less than 50% of the uterine wall in 60% of
patients [18] and misses 11% of endometrial cancers [19]. Endo-
metrial sampling was once believed to be a better alternative
because it can be performed in an ofﬁce setting without anesthesia.
After extensive studies, it proved to be less accurate than traditional
D&C [8,9,13,20]. The apparent advantage that TCR has over D&C is
that direct visualization of the lesion make targeted biopsies highly
feasible. In a systematic review, Clark et al [21] reported that hys-
teroscopic diagnosis has a positive predictive value of 78.5% in
diagnosing endometrial cancer and a negative predictive value of
0.6%, which further aids achieving a well-targeted biopsy.
Discrepancies between the initial and ﬁnal pathology can
change the risk of advanced disease and subsequently under-
treating patients. In the past, because of a signiﬁcant number of
upgrades, some surgeons may elect to overtreat and perform
staging surgery for low-risk patients [5,6]. However, complete
lymph node dissection for low-risk disease has not been proven to
improve survival [5,6]; therefore, it is possible that womenwith an
initial Grade 1 or 2 diagnosis with minimal myometrium invasion
but ﬁnal Grade 3 disease would not receive a complete lymph node
dissection. Therefore, the extrauterine status cannot be determined
and may result in inappropriate treatment planning. Undertreat-
ment could lead to rapid progression, a poorer outcome, and
increased use of adjuvant therapy [12], whereas overtreating could
Table 1
Patient characteristics.
Variable TCR D&C p
No. of patients 76 127
Age (y) 49.7 (25e77) 54.2 (31e83) 0.378
Preoperative histology grade 0.309
1 37 (48.7) 79 (62.2)
2 20(26.3) 27 (21.3)
3 19 (25.0) 21 (16.5)
Histiotype 0.358
Endometrioid 71 (93.4) 119 (93.7)
Mixed (papillary serous) 1 (1.3) 4 (3.1)
Mixed (clear cell) 3 (3.9) 4 (3.1)
Mixed (mucinous) 1 (1.3) 0 (0)
Final histology 0.200
1 35 (46.1) 70 (55.1)
2 21 (27.6) 29 (22.8)
3 20 (26.3) 28 (22.0)
Pelvic lymph nodes resected
(average)
18.5 16.6
Para-aortic lymph nodes
resected (average)
4.1 2.7
Myometrial invasion 0.066
Limited to endometrium 36 (47.7) 47 (37.0)
50% 29 (38.2) 55 (43.3)
>50% 11 (14.5) 25 (19.6)
Lymphovascular space invasion 0.416
Positive 12 (15.8) 18 (14.2)
Negative 64 (84.2) 109 (85.8)
Cervical invasion 0.400
Positive 2 (0.26) 9 (7.1)
Negative 74 (97.4) 118 (92.9)
Adnexa invasion 0.411
Preserved ovaries/ovaries absent 3 (3.9) 3 (2.4)
Positive 6 (7.9) 7 (5.5)
Negative 67 (88.1) 117 (92.1)
Washing cytology 0.327
No sample taken 4 (5.2) 12 (9.4)
Positive 3 (3.9) 3 (2.3)
Negative 69 (90.8) 112 (88.2)
Radiotherapy 0.416
Yes 17(22.4) 23 (18.1)
No 59 (77.6) 104 (81.9)
Data are presented as n (%) or Mean (range), unless otherwise indicated.
D&C ¼ dilation and curettage; TCR ¼ transcervical resectoscopy.
Table 3
The dilation and curettage histological grade, compared to the hysterectomy his-
tological grade.a,b
Final pathology
D&C Grade 1 2 3
1 70 (55.1) 8 (6.3) 2 (1.6)
2 d 20 (15.7) 6 (4.7)
3 d d 21 (16.5)
Data are presented as n (%).
D&C ¼ dilation and curettage.
a The number of positive washing cytology results: 3 (Stage IA, Grade 1; Stage
IIIC2, Grade 3; and Stage IA, Grade 3).
b The two-sample test proportions compared D&C1 versus hysterectomy1,
p ¼ 0.002; D&C2 versus hysterectomy 2, p ¼ 0.011; and D&C123 versus hysterec-
tomy 123, p ¼ < 0.001; kappa ¼ 0.7789.
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imperative to the surgeon's intraoperative behavior, and warrants
further investigation for a more accurate diagnostic method.
A prominent concern of using TCR as a diagnostic tool is that it
does not have a statistically increased risk of transtubal dissemi-
nation; however, this retrospective study was not powered to
adequately assess this parameter [23,24]. However, further studies,
which include a meta-analysis, have revealed that the spread is
clinically insigniﬁcant and that there is no evidence to support an
association between preoperative hysteroscopic examination and aTable 2
The transcervical resectoscopy histological grade, compared to the hysterectomy
histological grade.a,b
Final pathology, n (%)
TCR Grade 1 2 3
1 35 (46.0) 1 (1.3) 1 (1.3)
2 d 20 (26.3) d
3 d d 19 (25.0)
TCR ¼ transcervical resectoscopy.
a The number of positive washing cytology results: 3 (Stage IA, Grade 2; Stage IIIA,
Grade 3; Stage IIIC1, grade 3).
b The two-sample test proportions compare TCR1 versus hysterectomy1,
p ¼ 0.183; TCR123 versus hysterectomy123; p ¼ 0.181; kappa ¼ 0.9587.worse prognosis [25,26]. Furthermore, TCR has a similar risk of
intraperitoneal spread as D&C [27]. Our experience and results are
concurrent with these ﬁndings and revealed only three positive
intraperitoneal washings in the TCR group, of which two patients
had Stage III disease. Our D&C group had a similar number of
positive peritoneal washings with only one patient with Stage III
and two patients with Stage IA diagnoses.
A possible explanation for the inconsistency with our series and
other studies could be in the technique and operator during TCR. At
our institution, the same minimally invasive surgical team per-
formed all TCR procedures, which decreased the incidence of any
change in technique and unequivocal expertise. When there was a
suspicion of endometrial cancer, our surgeons took extra care to
ensure that the cervix was overdilated and high ﬂow and low
pressure (<80 mmHg) were maintained in the uterus at all times.
On retrospectively examining these cases, we nevertheless ques-
tion the hypothesis that the distension media during hysteroscopy
causes peritoneal spread. To our knowledge, there is insufﬁcient
evidence to reject other mechanisms of inducing intraperitoneal
spread such as uterine contractions during the endometrial biopsy
procedure.
From our study's ﬁndings, we can conclude that TCR has a
signiﬁcantly lower percentage of upgraded histological ﬁndings,
compared to D&C, and it does not have a higher risk of transtubal
peritoneal spread of cancer cells into the peritoneal cavity, despite
conﬂicting evidence of earlier studies [23,24]. Given the afore-
mentioned beneﬁts of TCR, we believe that, compared to D&C, TCR
may provide a precise and accurate staging plan in the preoperative
risk evaluation of patients with endometrial cancer. However,
because of the small number of patients in our study, the results
should be evaluated carefully. A larger randomized control trial
should be performed for further evaluation and conﬁrmation of
these preliminary results.Table 4
Para-aortic lymph node dissection for patients with Grade 3 tumors.a,*
Low preoperative risk ¼>
high postoperative risk
High preoperative risk ¼>
high postoperative risk
Without PALND 6 (66.7) 3 (12.5)
With PALND 3 (33.3) 21 (87.5)
Total 9 24
Data are presented as n (%).
* Fisher's exact test, p ¼ 0.005.
PALND ¼ para-aortic lymph node dissection.
a Patients whose preoperative imaging could not assess depth of myometrial
invasion are not included.
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